(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
Doris Riether, Biberach an der Riss (DE); Florian Paul Christian Binder, Maselheim (DE); Henri Doods, Warthausen (DE); Stephan Georg Mueller, Warthausen (DE); Janet Rachel Nicholson, Oberhoefen (DE); and Achim Sauer, Ravensburg-Torkenweiler (DE)
Assigned to Centrexion Therapeutics Corporation, Boston, MA (US)
Filed by Centrexion Therapeutics Corporation, Boston, MA (US)
Filed on Aug. 10, 2021, as Appl. No. 17/398,155.
Application 17/398,155 is a continuation of application No. 16/749,412, filed on Jan. 22, 2020, granted, now 11,084,810.
Application 16/749,412 is a continuation of application No. 16/143,523, filed on Sep. 27, 2018, granted, now 10,570,125, issued on Feb. 25, 2020.
Application 16/143,523 is a continuation of application No. 15/491,035, filed on Apr. 19, 2017, granted, now 10,112,934, issued on Oct. 30, 2018.
Application 15/491,035 is a continuation of application No. 14/891,051, granted, now 9,650,370, issued on May 16, 2017, previously published as PCT/EP2014/060033, filed on May 16, 2014.
Claims priority of application No. 13168165 (EP), filed on May 17, 2013.
1. A method of treating diabetic neuropathy, comprising administering to a human being an effective amount of a compound selected from the group consisting of
and a pharmaceutically acceptable salt thereof, to treat the diabetic neuropathy.